IL160052A0 - Diagnostic and pharmaceutical compositions containing microorganisms or cells including a detectable protein - Google Patents

Diagnostic and pharmaceutical compositions containing microorganisms or cells including a detectable protein

Info

Publication number
IL160052A0
IL160052A0 IL16005202A IL16005202A IL160052A0 IL 160052 A0 IL160052 A0 IL 160052A0 IL 16005202 A IL16005202 A IL 16005202A IL 16005202 A IL16005202 A IL 16005202A IL 160052 A0 IL160052 A0 IL 160052A0
Authority
IL
Israel
Prior art keywords
protein
diagnostic
pharmaceutical compositions
compositions containing
cells including
Prior art date
Application number
IL16005202A
Other languages
English (en)
Original Assignee
Aladar A Szalay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01118417A external-priority patent/EP1281772A1/de
Application filed by Aladar A Szalay filed Critical Aladar A Szalay
Publication of IL160052A0 publication Critical patent/IL160052A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL16005202A 2001-07-31 2002-07-31 Diagnostic and pharmaceutical compositions containing microorganisms or cells including a detectable protein IL160052A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118417A EP1281772A1 (de) 2001-07-31 2001-07-31 Lichtemittierende Mikroorganismen und Zellen zum Nachweis und zur Therapie von Krebs
EP01125911A EP1281767A3 (de) 2001-07-31 2001-10-30 Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
PCT/IB2002/004767 WO2003014380A2 (en) 2001-07-31 2002-07-31 Microoroganisms and cells for diagnosis and therapy of tumors

Publications (1)

Publication Number Publication Date
IL160052A0 true IL160052A0 (en) 2004-06-20

Family

ID=26076668

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16005202A IL160052A0 (en) 2001-07-31 2002-07-31 Diagnostic and pharmaceutical compositions containing microorganisms or cells including a detectable protein

Country Status (17)

Country Link
US (7) US20030059400A1 (de)
EP (2) EP1281767A3 (de)
KR (3) KR20040054668A (de)
CN (1) CN100415897C (de)
AT (2) ATE452205T1 (de)
BR (1) BR0211546A (de)
CA (1) CA2456055C (de)
DE (3) DE60222910D1 (de)
IL (1) IL160052A0 (de)
MX (1) MXPA04000882A (de)
NO (1) NO20040428L (de)
NZ (1) NZ530818A (de)
PL (1) PL374326A1 (de)
RU (1) RU2357754C2 (de)
SG (1) SG168404A1 (de)
TR (1) TR200400149T2 (de)
WO (1) WO2003014380A2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AU749695B2 (en) * 1997-09-10 2002-07-04 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
CA2470411C (en) * 2001-12-31 2015-07-07 Anticancer, Inc. System for monitoring bacterial tumor treatment
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (de) 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
AU2003285930A1 (en) * 2002-10-21 2004-05-13 The Regents Of The University Of California Optical imagiong of renilla luciferase reporter gene expression in living organisms
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
AU2004289953B2 (en) * 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
US7155274B1 (en) 2003-11-21 2006-12-26 Imaging Diagnostic Systems, Inc. Optical computed tomography scanner for small laboratory animals
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) * 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US7883535B2 (en) * 2004-11-09 2011-02-08 Institut National D'optique Device and method for transmitting multiple optically-encoded stimulation signals to multiple cell locations
CN102423665B (zh) 2005-04-25 2015-04-15 高级技术材料公司 具有空检测能力的基于衬里的液体储存和分配系统
US20070231833A1 (en) * 2005-05-23 2007-10-04 Arcidiacono Steven M Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest
KR20080039373A (ko) 2005-06-06 2008-05-07 어드밴스드 테크놀러지 머티리얼즈, 인코포레이티드 유체 저장 및 분배 시스템과 프로세스
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
EP2171071B1 (de) 2007-06-15 2015-08-05 Genelux Corporation Für ein natriumabhängiges transporterprotein codierende vacciniavirus-vektoren zur bildlichen darstellung und/oder behandlung von tumoren
WO2009011924A1 (en) 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
US20110135575A1 (en) * 2007-08-28 2011-06-09 Massachusetts Institute Of Technology Metalloprotein mri contrast agents and related methods
US20090074670A1 (en) * 2007-09-07 2009-03-19 Yousef Haik Hyperthermia Therapeutic Agent Delivery System
US20090068112A1 (en) * 2007-09-11 2009-03-12 Yousef Haik Magnetic Nanoparticles for Imaging
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
US20090176260A1 (en) * 2007-12-04 2009-07-09 Joseph Ching-Ming Wu Double-fusion human embryonic stem cells, methods of making double-fusion human embryonic stem cells, triple-fusion human embryonic stem cells, methods of making triple-fusion human embryonic stem cells, and methods of monitoring double-fusion human embryonic stem cells and triple-fusion human embryonic stem cells
US8357486B2 (en) 2008-01-11 2013-01-22 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
EP2300023A2 (de) * 2008-05-16 2011-03-30 Genelux Corporation Mikroorganismen zur prävention und behandlung von neoplasien neben einer zelltherapie
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
GB2472790A (en) * 2009-08-18 2011-02-23 Laurence Christian Hayes Dermatological preparations comprising microbes.
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
EP2593796A4 (de) 2010-07-16 2016-07-27 Auckland Uniservices Ltd Bakterielle nitroreduktase-enzyme und verfahren dafür
PL2598165T3 (pl) 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
WO2012040105A2 (en) * 2010-09-21 2012-03-29 Kansas State University Research Foundation Renilla/gaussia transfected cells as a light source for in-situ photodynamic therapy of cancer
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US8828681B2 (en) 2012-01-13 2014-09-09 Bell Biosystems, Inc. Host cells with artificial endosymbionts
US10076579B2 (en) 2012-01-13 2018-09-18 Bell Biosystems, Inc. Host cells with artificial endosymbionts
US9023612B2 (en) 2012-01-13 2015-05-05 Bell Biosystems, Inc. Eukaryotic cells with artificial endosymbionts for multimodal detection
US8956873B2 (en) 2012-01-13 2015-02-17 Bell Biosystems, Inc. Host cells with artificial endosymbionts
DK2823040T3 (en) * 2012-03-06 2018-11-19 Cellect Biotherapeutics Ltd DEVICES AND METHODS FOR SELECTING APOPTOSE SIGNALING RESISTANT CELLS AND APPLICATIONS THEREOF
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014145785A1 (en) 2013-03-15 2014-09-18 Bell Biosystems, Llc Host cells with artificial endosymbionts
GB201310917D0 (en) * 2013-06-19 2013-07-31 Cancer Res Inst Royal Vaccinia virus for gene-directed enzyme prodrug therapy
WO2015034962A1 (en) * 2013-09-03 2015-03-12 Bell Biosystems, Inc. Host cell modification with artificial endosymbionts
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
SG11201606324TA (en) * 2014-02-13 2016-08-30 Bell Biosystems Inc Systems for making host cells with artificial endosymbionts
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
RU2020120075A (ru) 2014-05-02 2020-07-03 Кью Байолоджикс Инк. Противомикробная иммуномодуляция
CN104162175B (zh) * 2014-06-18 2017-02-01 东华大学 功能化的基于树状大分子的spect‑ct双模态成像造影剂及其制备方法
WO2016011336A1 (en) 2014-07-17 2016-01-21 Western Michigan University Research Foundation Composition for treating cancerous cells and a method therefor
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107365799A (zh) * 2017-08-08 2017-11-21 四川省肿瘤医院 Sod2慢病毒载体、构建方法及其在靶向性辐射防护和肿瘤增敏中的应用
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CA3177467A1 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
JP7329593B2 (ja) 2018-11-06 2023-08-18 カリディ・バイオセラピューティクス・インコーポレイテッド 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3176660A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
GB201914096D0 (en) * 2019-09-30 2019-11-13 Rna Guardian Ltd Cancer Biomarker
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US11297054B1 (en) * 2020-10-06 2022-04-05 International Business Machines Corporation Authentication system(s) with multiple authentication modes using one-time passwords of increased security
RU2755010C1 (ru) * 2021-01-26 2021-09-09 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ диагностики рака ободочной кишки
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN118064333B (zh) * 2024-04-18 2024-07-05 青岛诺和诺康生物科技有限公司 一株唾液联合乳杆菌及其在制备改善皮肤色泽产品中的应用

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165465A (en) * 1875-07-13 Improvement in paper-weights
US9015A (en) * 1852-06-15 Manufacture of granular fuel from brush-wood and twigs
US228330A (en) * 1880-06-01 Advertising checker-board
US31681A (en) * 1861-03-12 Puhchifg-machine
US886906A (en) * 1907-05-20 1908-05-05 Katie Putnam Emery Cherry-pitter.
JPS542336A (en) * 1977-06-06 1979-01-09 Meiji Seika Kaisha Ltd Preventive and remedy for viral diseases
EP0037441B1 (de) 1980-03-10 1984-05-09 Seiji Arakawa Pharmazeutische Zusammensetzungen zur zellulären Immunopotentialisation und als Antitumor-Mittel, Verfahren zu ihrer Herstellung und der darin verwendete Mikroorganismus
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
US4442203A (en) 1981-06-30 1984-04-10 Massachusetts Institute Of Technology Gene amplification assay for detecting tumor promoters
US5378457A (en) 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4778759A (en) 1982-07-09 1988-10-18 Boyce, Thompson Institute For Plant Research, Inc. Genetic engineering in cyanobacteria
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5221623A (en) 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US5866136A (en) 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE68919846T2 (de) 1988-02-12 1995-07-06 Commw Scient Ind Res Org Poxvirus-vektoren.
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
ATE219519T1 (de) 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
WO1991007989A1 (en) * 1989-11-28 1991-06-13 Universite Laval A method of inactivating human immunodeficiency virus
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5212082A (en) 1991-03-13 1993-05-18 New York University Genetically modified tyrosine hydroxylase and uses thereof
US5800829A (en) 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5718902A (en) 1991-06-17 1998-02-17 The Regents Of The University Of California Double recombinant vaccinia virus vaccines
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
ATE204470T1 (de) 1992-05-29 2001-09-15 Vivorx Inc Mikroverkapselung von zellen
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US6491905B1 (en) 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
WO1995031105A1 (en) * 1994-05-13 1995-11-23 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6217847B1 (en) 1994-07-01 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5853717A (en) 1994-07-20 1998-12-29 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5853385A (en) 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
EP0784483B1 (de) 1994-10-03 2000-11-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5693533A (en) 1994-12-07 1997-12-02 The Goodwin Institue For Cancer Research Human breast carcinoma cell line capable of production of a spontaneously metastasizing tumor in animals for use in anticancer drug testing
US6150170A (en) 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6503703B1 (en) 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US20020160970A1 (en) 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5710137A (en) 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US5842431A (en) 1997-02-19 1998-12-01 Wu; Chong-Ming Rotating shuttle and presser plate arrangement
EP0979298B1 (de) * 1997-04-28 2008-06-11 Anticancer, Inc. Metastasemodelle unter verwendung des grün-fluoreszierenden proteins
US6232523B1 (en) 1997-04-28 2001-05-15 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6251384B1 (en) 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6265557B1 (en) 1997-05-09 2001-07-24 Loma Linda University Medical Center ABO histo-blood group O alleles of the baboon
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
DE29924318U1 (de) 1999-01-14 2002-09-19 Fleischmann, Wilhelm, Dr.med., 74321 Bietigheim-Bissingen Verbandsmaterial
US6713293B1 (en) 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6511967B1 (en) * 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
CA2375189C (en) 1999-05-28 2010-02-09 The Government Of The United States Of America A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US6627190B2 (en) 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
WO2001005229A1 (en) * 1999-07-15 2001-01-25 The General Hospital Corporation Non-defective epstein-barr viral vector
CA2384496A1 (en) * 1999-09-08 2001-03-15 Xenogen Corporation Luciferase expression cassettes and methods of use
AU7856100A (en) * 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
EP1414499A4 (de) * 1999-10-04 2004-05-06 Vion Pharmaceuticals Inc Nicht invasives tumor-imaging mittels tumorgerichteter bakterien
US6589531B1 (en) 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
EP1254250B1 (de) 2000-01-26 2005-03-23 Loma Linda University Verfahren zur evaluierung von inplantierbaren materialien
US6448073B1 (en) 2000-01-28 2002-09-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
DE60137501D1 (de) 2000-03-17 2009-03-12 Anticancer Inc Optisches abbildungssystem zur darstellung der genexpression des gesamten körpers und anwendungen
DE10013511A1 (de) * 2000-03-20 2001-10-11 Brand Gmbh & Co Kg Mehrkanal-Pipettiereinrichtung sowie Pipettenschaft dafür
WO2001075182A1 (fr) 2000-04-04 2001-10-11 Nippon Steel Corporation Profile en acier lamine en forme de h a microstructure uniforme et proprietes mecaniques uniformes ; procede de fabrication
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
CA2342040C (en) 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
WO2003006069A1 (en) 2001-07-09 2003-01-23 Anticancer, Inc. Imaging infection using fluorescent protein as a marker
US20030021768A1 (en) 2001-07-23 2003-01-30 Yuqiao Shen Viral mutants that selectively replicate in targeted human cancer cells
EP1281772A1 (de) 2001-07-31 2003-02-05 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen zum Nachweis und zur Therapie von Krebs
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
DK1446012T3 (da) 2001-11-21 2013-10-14 Univ Johns Hopkins Bakteriolytisk kombinationsterapi til behandling af tumorer
EP1450854A2 (de) 2001-11-30 2004-09-01 Isis Innovation Limited Impfstoff
CA2470411C (en) 2001-12-31 2015-07-07 Anticancer, Inc. System for monitoring bacterial tumor treatment
EP1487463A2 (de) 2002-03-02 2004-12-22 Board Of Regents The University Of Texas System Lokale produktion und/oder abgabe von anti-krebsmitteln durch vorläufer von stromazellen
WO2003078640A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
US20030213007A1 (en) 2002-03-27 2003-11-13 Slattery Charles Wilbur Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof
WO2003102168A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
EP1369491A1 (de) 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
KR20130012595A (ko) 2002-08-12 2013-02-04 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
WO2004044175A2 (en) 2002-11-12 2004-05-27 Anticancer, Inc. Fluorescence guided cell capture
AU2004289953B2 (en) 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
EP1526185B1 (de) 2003-10-22 2012-09-12 Genelux Corporation Verwendung von Mikroorganismen oder Zellen zur Autoimmunisierung gegen Tumoren
EP1512746B1 (de) 2003-08-14 2009-10-07 Genelux Corporation Methode zur Herstellung eines Polypeptides, einer RNA oder einer anderen Verbindung in Tumorgewebe
WO2005057488A2 (en) 2003-12-03 2005-06-23 Anticancer, Inc. Modular system for multi-color, whole body fluorescence imaging
KR20070003879A (ko) 2004-01-26 2007-01-05 안티캔서, 인코포레이티드 휴대용 관찰 시스템을 사용한 전신 이미징
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
ATE516370T1 (de) 2005-12-22 2011-07-15 Sloan Kettering Inst Cancer Verfahren zur erfassung von krebszellen unter verwendung eines virus
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US20090081639A1 (en) 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
EP2171071B1 (de) 2007-06-15 2015-08-05 Genelux Corporation Für ein natriumabhängiges transporterprotein codierende vacciniavirus-vektoren zur bildlichen darstellung und/oder behandlung von tumoren
WO2009011924A1 (en) 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
US8357486B2 (en) 2008-01-11 2013-01-22 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
EP2300023A2 (de) 2008-05-16 2011-03-30 Genelux Corporation Mikroorganismen zur prävention und behandlung von neoplasien neben einer zelltherapie
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic

Also Published As

Publication number Publication date
DE60222910T4 (de) 2009-01-15
WO2003014380A2 (en) 2003-02-20
US8568707B2 (en) 2013-10-29
NO20040428L (no) 2004-03-31
TR200400149T2 (tr) 2005-10-21
EP1414994B9 (de) 2008-11-12
EP1281767A3 (de) 2003-05-28
EP1281767A2 (de) 2003-02-05
WO2003014380A3 (en) 2004-01-22
HK1065826A1 (en) 2005-03-04
PL374326A1 (en) 2005-10-17
NZ530818A (en) 2007-07-27
KR20080108600A (ko) 2008-12-15
US20090117047A1 (en) 2009-05-07
EP1414994B1 (de) 2007-10-10
MXPA04000882A (es) 2005-06-06
DE60234793D1 (de) 2010-01-28
CA2456055C (en) 2012-01-24
RU2357754C2 (ru) 2009-06-10
DE60222910D1 (de) 2007-11-22
ATE452205T1 (de) 2010-01-15
SG168404A1 (en) 2011-02-28
CN1617935A (zh) 2005-05-18
BR0211546A (pt) 2004-07-13
KR100987574B1 (ko) 2010-10-12
KR20100063143A (ko) 2010-06-10
KR20040054668A (ko) 2004-06-25
US20030059400A1 (en) 2003-03-27
US8642257B2 (en) 2014-02-04
CN100415897C (zh) 2008-09-03
US20090117048A1 (en) 2009-05-07
KR100987598B1 (ko) 2010-10-12
EP1414994A2 (de) 2004-05-06
US20050069491A1 (en) 2005-03-31
CA2456055A1 (en) 2003-02-20
DE60222910T2 (de) 2008-07-24
ATE375401T1 (de) 2007-10-15
US20040234455A1 (en) 2004-11-25
RU2004106155A (ru) 2005-07-10
US20090117049A1 (en) 2009-05-07
US8586022B2 (en) 2013-11-19
US20090123382A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
IL160052A0 (en) Diagnostic and pharmaceutical compositions containing microorganisms or cells including a detectable protein
IL165350A0 (en) Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
HK1053985A1 (zh) 人類多肽引起或導致殺死細胞，包括淋巴腫瘤細胞
ES2142953T3 (es) Factor de crecimiento y diferenciacion de la familia del tgf-beta.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
AU3263995A (en) Cell cycle regulated repressor and dna element
AU4050801A (en) Intra-tumoral administration of il-12 encoding nucleic acid molecules
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU2001286699A1 (en) Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
AU3477295A (en) Modified proteins
IL150984A0 (en) Modified cytokines for use in cancer therapy
WO2003008430A3 (en) Porphyrin derivatives for photodynamic therapy
IL141984A0 (en) Akt nucleic acids, polypeptides, and uses thereof
AU5305000A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
DE60132443D1 (de) In lebenden zielzellen
AU2002364302A1 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
DE69909041D1 (de) Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
EP1914316A3 (de) Mikroorganismen und Zellen zur Diagnose und Behandlung von Tumoren
EP2272529A3 (de) DNA-Impstoff kombiniert mit einen Apoptoseauslöser von Tumorzellen
AU5619700A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
DE69730967D1 (en) Human dnase ii
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques